Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: Comparison with integrated FDG-PET/non-contrast- enhanced CT and enhanced CT

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 8, 2008, Pages 1439-1448

  Kitajima, Kazuhiro ^a,c   Murakami, Koji ^a   Yamasaki, Erena ^a   Domeki, Yasushi ^a   Kaji, Yasushi ^a   Fukasawa, Ichio ^a   Inaba, Noriyuki ^a   Suganuma, Narufumi ^b   Sugimura, Kazuro ^c  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

18F FDG; Ovarian cancer; PET CT; Recurrence

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE; IOMEPROLE 300; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IOPAMIDOL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; SYSTEMS INTEGRATION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 48149102304     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-008-0776-3     Document Type: Article

References (43)

1. RE Bristow LR Duska NC Lambrou EK Fishmann MJ O'Neill EL Trimble 2000 A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography Cancer. 89 1532 1540
2. SA Cannistra 2004 Cancer of the ovary N Engl J Med. 351 2519 2529
3. WP McGuire WJ Hoskins MF Brady PR Kucera EE Partridge KY Look 1996 Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N Eng J Med. 334 1 6
4. J Dauplat G Le Bouedec C Pomel C Scherer 2000 Cytoreductive surgery for advanced stages of ovarian cancer Semin Surg Oncol. 19 42 48
5. RT Grrenlee MB Hill Harmon T Murray M Thun 2001 Cancer statistics 2001 CA Cancer J Clin. 51 15 36
6. JM Niloff RC Bast Jr EM Schaetzl RC Knapp 1985 Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer Am J Obstet Gynecol. 151 981 986
7. G Rustin M Tuxen 1996 Use of CA 125 in follow-up of ovarian cancer Lancet. 348 191 192
8. GJS Rustin M Marples AE Nelstrop M Mahmoudi T Meyer 2001 Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J Clin Oncol. 19 4054 4057
9. V De Rosa ML Mangoni di Stefano A Brunetti C Caraco R Graziano MS Gallo 1995 Computed tomography and second-look surgery in ovarian cancer patients. Correlation, actual role and limitations of CT scan Eur J Gynaecol Oncol. 16 123 129
10. F Ferrozzi D Bova F DeChiara G Garlaschi F Draghi G Cocconi 1998 Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history Clin Imag. 22 364 370
11. E Topuz A Aydiner P Saip Y Eralp F Tas Y Salihoglu 2000 Correlation of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer Eur J Gynaecol Oncol. 21 599 602
12. SA Funt H Hricak N Abu-Rustum M Mazumdar H Felderman DS Chi 2004 Role of CT in the management of recurrent ovarian cancer AJR Am J Roentgenol. 182 393 398
13. R Forstner H Hricak KA Occhipinti CB Powell SD Frankel JL Stern 1995 Ovarian cancer: staging with CT and MR imaging Radiology. 19 619 626
14. J Ricke J Sehouli C Hach EL Hanninen W Lichtenegger R Felix 2003 Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer Eur Radiol. 13 943 949
15. RN Low B Duggan RM Barone F Saleh SY Thomas Song 2005 Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year Radiology. 235 918 926
16. HK Pannu RE Bristow FJ Montz EK Fishman 2003 Multidetector CT of peritoneal carcinomatosis from ovarian cancer RadioGraphics. 23 687 701
17. GJ Cook MN Maisey I Fogelman 1999 Normal variants, artifacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine Eur J Nucl Med. 26 1363 1378
18. L Kostakoglu H Agress Jr SJ Goldsmith 2003 Clinical role of FDG PET in evaluation of cancer patients Radiographics. 23 315 340
19. T Beyer DW Townsend T Brun PE Kinahan M Charron R Roddy 2000 A combined PET/CT scanner for clinical oncology J Nucl Med. 41 1369 1379
20. R Bar-Shalom N Yefremov L Guralnik D Gaitini A Frenkel A Kuten 2003 Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management J Nucl Med. 44 1200 1209
21. M Zimmy W Siggelkow W Schroder B Nowak S Biemann W Rath 2001 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer Gynecol Oncol. 83 310 315
22. PG Rose P Faulhaber F Miraldi FW Abdul-Karim 2001 Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: Correlation with second-look laparotomy Gynecol Oncol. 82 17 21
23. WC Chang YC Hung CH Kao RF Yen YY Shen CC Lin 2002 Usefulness of whole body positron emission tomography (PET) with 18F-fluoro-2-deoxyglucose (FDG) to detect recurrent ovarian cancer based to asymptomatically elevated serum levels of tumor marker (CA-125 antigen) Neoplasma. 49 329 333
24. 18F]fluoro-2-deoxy-d- glucose positron emission tomography Cancer. 100 544 552
25. S Sironi C Messa G Mangili B Zangheri G Aletti E Garevaglia 2004 Integrated FDG PET/CT in patients with persistent ovarian cancer: Correlation with histologic findings Radiology. 233 433 440
26. HK Pannu C Cohade RE Bristow EK Fishman RL Wahl 2004 PET-CT detection of abdominal recurrence of ovarian cancer: radiologic-surgical correlation Abdom Imaging. 39 398 403
27. EAM Hauth G Antoch J Stattaus H Kuehl P Veit A Bosckisch 2005 Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer Eur J of Radiol. 56 263 268
28. RE Bristow RL Giuntoli II HK Pannu RD Schulick EK Fishman RL Wahl 2005 Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes Gynecol Oncol. 99 294 300
29. G Mangili M Picchio S Sironi R Vigano E Rabaiotti D Bornaghi 2007 Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer Eur J Nucl Med Mol Imaging. 34 658 666
30. MM Thrall JA DeLoia H Gallion N Avril 2007 Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer Gynecol Oncol. 105 17 22
31. 18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings Eur J Nucl Med Mol Imaging. 34 480 486
32. S Sebastian SI Lee NS Horowitz JA Scott AJ Fischman JF Simeone 2008 PET-CT vs. CT alone in ovarian cancer recurrence Abdom Imaging. 33 112 118
33. G Antoch J Stattaus AT Nemat S Marnitz T Beyer H Kuehl 2003 Non-small cell lung cancer: Dual-modality PET/CT in preoperative staging Radiology. 229 526 533
34. G Antoch N Saoudi H Kuehl G Dahmen SP Muller T Beyer 2004 Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-d-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET J Clin Oncol. 22 4357 4368
35. CM Tempany KH Zou SG Silverman DL Brown AB Kurtz BJ McNeil 2000 Staging of advanced ovarian cancer: comparison of imaging modalities-report from the Radiological Diagnostic Oncology Group Radiology. 215 761 767
36. ER Coleman D Delbeke MJ Guiberteau PS Conti HD Royal JC Weinreb 2005 Concurrent PET/CT with an integrated imaging system: intersociety dialogue from the joint working group of the American College of Radiology, the Society of Nuclear Medicine, and the Society of Computed Body Tomography and Magnetic Resonance J Nucl Med. 46 1225 1239
37. C Cohade RL Wahl 2003 Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography: clinical use, interpretation methods, diagnostic improvements Semi Nucl Med. 33 228 237
38. NG Schaefer TF Hany C Taverna C Taverna B Seifert KD Stumpe 2004 Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG-PET and CT at staging and restaging-Do we need contrast-enhanced CT Radiology. 232 823 829
39. B Rodriguez-Vigil N Gomez-Leon I Pinilla D Hernandez-Maraver J Coya L Martin-Curto 2006 PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT J Nucl Med. 47 1643 1648
40. O Mawlawi JJ Erasmus RF Munden T Pan A Knight HA Macapinlac 2006 Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation AJR Am J Roentgenol. 186 308 119
41. 18F-FDG PET/CT J Nucl Med. 45 56 65
42. AC Pfannenberg P Aschoff K Brechtel M Muller R Bares F Paulsen 2007 Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer Eur J Nucl Med Mol Imaging. 34 36 44
43. AC Pfannenberg P Aschoff K Brechtel M Muller M Klein R Bares 2007 Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging Br J Radiol. 80 437 445